Psychiatric features in high-functioning adult brothers with fragile x spectrum disorders.

MIND Medical Investigation of Neurodevelopmental Disorders Institute (Drs Schneider, Tassone, Hagerman, and Hessl) and Departments of Psychiatry and Behavioral Sciences (Drs Seritan and Hessl), Biochemistry (Dr Tassone), Psychology (Dr Rivera), and Pediatrics (Drs Schneider and Hagerman), University of California-Davis Medical Center, Sacramento Corresponding author. Email: [email protected] Potential conflicts of interest: Dr Hagerman has been a consultant for Novartis and has received grant/research support from Seaside Therapeutics, Novartis, Roche, Forest, and Curemark. Dr Hessl has been a consultant for Roche, Seaside Therapeutics, and Novartis; has received grant/research support from the National Institute of Mental Health; and has received honoraria from Adelphi. Drs Schneider, Seritan, Tassone, and Rivera report no potential conflicts of interest relevant to the subject of this letter. Funding/support: This work was supported by National Institutes of Health (NIH) grant MH078041 to Dr Hessl, grants HD036071 and AG032115 to Dr Hagerman, and grant HD02274 to Dr Tassone; NIH/National Institute on Aging grant RL1AG032115 (overall PI: Dr P. J. Hagerman; component PI: Dr R. J. Hagerman); NIH/National Institute of Mental Health grant R01MH078041 (PIs: Drs Hessl and Rivera); and Health and Human Services Administration of Developmental Disabilities grant 90DD0596.